64,431 Shares in Perrigo Company plc $PRGO Acquired by M&T Bank Corp

M&T Bank Corp bought a new position in shares of Perrigo Company plc (NYSE:PRGO) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 64,431 shares of the company’s stock, valued at approximately $897,000.

Several other hedge funds have also added to or reduced their stakes in PRGO. Geneos Wealth Management Inc. boosted its position in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the period. CWM LLC boosted its position in Perrigo by 230.0% during the 4th quarter. CWM LLC now owns 2,191 shares of the company’s stock worth $31,000 after buying an additional 1,527 shares during the period. Key Capital Management INC acquired a new stake in Perrigo during the 4th quarter worth approximately $36,000. Jones Financial Companies Lllp boosted its position in Perrigo by 89.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after buying an additional 838 shares during the period. Finally, Kestra Investment Management LLC boosted its position in Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after buying an additional 642 shares during the period. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Canaccord Genuity Group lowered their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, February 27th. Weiss Ratings lowered shares of Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Finally, Argus upgraded shares of Perrigo to a “hold” rating in a report on Wednesday, January 14th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Perrigo currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Key Perrigo News

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Completed sale of branded Dermacosmetics business for up to €332.6M, with ~€305.6M upfront (≈€306M net proceeds) — Perrigo says proceeds will be used to reduce debt and streamline the portfolio under its “Three-S” plan, improving near-term liquidity and leverage metrics. Read More.
• Positive Sentiment: Board approved a quarterly cash dividend of $0.29/share (annualized $1.16), implying a ~9.8% yield — supports income-focused investors and can prop up demand for the shares ahead of the ex-dividend date (May 29, 2026). Read More.
• Positive Sentiment: Zacks Research upgraded Perrigo from “Strong Sell” to “Hold,” a step toward more constructive analyst sentiment that may reduce selling pressure. Read More.
• Neutral Sentiment: Zacks raised near‑term EPS forecasts (Q1, Q2 and FY estimates were nudged higher), which moderates downside risk but the firm’s messaging remains cautious; mix of slightly better estimates vs. lingering negative rating history. (No single-article link provided)
• Neutral Sentiment: Analyst/strategy piece on Seeking Alpha discusses a “thesis reset” and positioning — useful for longer-term investors but more interpretive than a direct catalyst. Read More.
• Negative Sentiment: Zacks preview flagged that analysts expect a decline in upcoming earnings and indicated Perrigo lacks the typical setup for an easy earnings beat; negative expectations around near-term results could continue to pressure the multiple. Read More.

Perrigo Stock Performance

NYSE:PRGO opened at $11.84 on Friday. The company has a fifty day moving average of $11.16 and a 200-day moving average of $13.90. The firm has a market capitalization of $1.63 billion, a P/E ratio of -1.15, a P/E/G ratio of 1.33 and a beta of 0.47. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. Perrigo Company plc has a twelve month low of $9.23 and a twelve month high of $28.43.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.80 by ($0.03). The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The business’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts anticipate that Perrigo Company plc will post 2.12 EPS for the current year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 9.8%. The ex-dividend date is Friday, May 29th. Perrigo’s payout ratio is -11.28%.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.